What is the current Hemoglobinopathies Treatment Market size?

The Hemoglobinopathies Treatment Market is projected to register a CAGR of 7% during the forecast period (2024-2029) Read More

Who are the key players in Hemoglobinopathies Treatment Market?

Sanofi S.A., Global Blood Therapeutics, Inc., bluebird bio, Inc., EMI Holding, Inc. and Celgene Corporation are the major companies operating in the Hemoglobinopathies Treatment Market. Read More

Which is the fastest growing region in Hemoglobinopathies Treatment Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029). Read More

Which region has the biggest share in Hemoglobinopathies Treatment Market?

In 2024, the North America accounts for the largest market share in Hemoglobinopathies Treatment Market. Read More

What years does this Hemoglobinopathies Treatment Market cover?

The report covers the Hemoglobinopathies Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Hemoglobinopathies Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Hemoglobinopathies Treatment Market Share

Statistics for the 2023 & 2024 Hemoglobinopathies Treatment market share, created by Mordor Intelligence™ Industry Reports. Hemoglobinopathies Treatment share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Market Share of Hemoglobinopathies Treatment Industry

Global hemoglobinopathies treatment market is moderately fragmented and competitive. Market players are focusing on new product launches, product innovations and geographical expansion. For instance, in May 2017, Sangamo Therapeutics and Pfizer announced a collaboration for the haemophilia A gene therapy. The key market players operating in the market include Sanofi S.A., Global Blood Therapeutics, Inc., bluebird bio, Inc. EMI Holding, Inc. and Celgene Corporation among others.